Communiqué from EXTRAordinary General Meeting in Prostatype Genomics AB (publ) held on 7 december 2023
Prostatype Genomics AB (publ), listed on the Nasdaq First North Growth Market, held an extraordinary general meeting today on 7 December 2023, whereby the following decisions were unanimously made. The extraordinary general meeting resolved to approve the board of directors’ resolution on 7 November 2023 to increase Prostatype Genomics share capital with a maximum of SEK 16,724,400.98 (the new quota value –SEK 0.01 – after the proposed reduction is applied) of which not more than SEK 11,946,000.70 refers to an increase due to an issue of shares, and not more than SEK 4,778,400.28 refers